Muller & Phipps (India) Ltd
Incorporated in 1917, Muller & Phipps (India) is engaged in marketing of over the counter medical preparation and home care products.
- Market Cap ₹ 14.7 Cr.
- Current Price ₹ 235
- High / Low ₹ 684 / 216
- Stock P/E
- Book Value ₹ -33.1
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Debtor days have increased from 90.9 to 111 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.67 | 4.50 | 3.47 | 3.40 | 3.13 | 3.74 | 3.61 | 3.97 | 3.67 | 3.91 | 4.14 | 5.80 | 5.34 | |
| 3.74 | 4.88 | 3.59 | 3.40 | 3.10 | 3.36 | 3.50 | 3.72 | 3.50 | 3.86 | 4.16 | 6.76 | 6.67 | |
| Operating Profit | -0.07 | -0.38 | -0.12 | 0.00 | 0.03 | 0.38 | 0.11 | 0.25 | 0.17 | 0.05 | -0.02 | -0.96 | -1.33 | 
| OPM % | -1.91% | -8.44% | -3.46% | 0.00% | 0.96% | 10.16% | 3.05% | 6.30% | 4.63% | 1.28% | -0.48% | -16.55% | -24.91% | 
| 0.18 | 1.14 | 0.38 | 0.30 | 0.18 | 0.08 | 0.38 | 1.61 | 0.38 | 0.26 | 0.83 | 0.28 | 1.29 | |
| Interest | 0.31 | 0.31 | 0.31 | 0.24 | 0.24 | 0.21 | 0.14 | 0.12 | 0.10 | 0.09 | 0.07 | 0.06 | 0.07 | 
| Depreciation | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 
| Profit before tax | -0.23 | 0.44 | -0.06 | 0.05 | -0.04 | 0.24 | 0.34 | 1.73 | 0.44 | 0.21 | 0.73 | -0.75 | -0.11 | 
| Tax % | 0.00% | 0.00% | 0.00% | 20.00% | 0.00% | 20.83% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| -0.23 | 0.44 | -0.06 | 0.03 | -0.04 | 0.19 | 0.34 | 1.73 | 0.44 | 0.21 | 0.73 | -0.75 | -0.11 | |
| EPS in Rs | -3.68 | 7.04 | -0.96 | 0.48 | -0.64 | 3.04 | 5.44 | 27.68 | 7.04 | 3.36 | 11.68 | -12.00 | -1.76 | 
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 3% | 
| 5 Years: | 10% | 
| 3 Years: | 16% | 
| TTM: | 26% | 
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % | 
| 5 Years: | % | 
| 3 Years: | % | 
| TTM: | -210% | 
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% | 
| 5 Years: | 49% | 
| 3 Years: | 1% | 
| 1 Year: | -66% | 
| Return on Equity | |
|---|---|
| 10 Years: | % | 
| 5 Years: | % | 
| 3 Years: | % | 
| Last Year: | % | 
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 
| Reserves | -5.96 | -5.52 | -5.58 | -5.52 | -5.55 | -5.35 | -5.00 | -3.30 | -2.87 | -2.66 | -1.93 | -2.70 | 
| 1.91 | 1.90 | 1.89 | 1.89 | 1.89 | 2.04 | 1.90 | 1.62 | 1.34 | 1.06 | 0.79 | 0.84 | |
| 7.84 | 7.66 | 7.55 | 7.60 | 7.51 | 7.50 | 7.36 | 5.73 | 5.74 | 5.95 | 5.77 | 6.95 | |
| Total Liabilities | 4.42 | 4.67 | 4.49 | 4.60 | 4.48 | 4.82 | 4.89 | 4.68 | 4.84 | 4.98 | 5.26 | 5.72 | 
| 0.09 | 0.08 | 0.07 | 0.04 | 0.05 | 0.04 | 0.07 | 0.07 | 0.06 | 0.05 | 0.06 | 0.06 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 
| 4.32 | 4.58 | 4.41 | 4.55 | 4.42 | 4.77 | 4.81 | 4.60 | 4.77 | 4.92 | 5.19 | 5.65 | |
| Total Assets | 4.42 | 4.67 | 4.49 | 4.60 | 4.48 | 4.82 | 4.89 | 4.68 | 4.84 | 4.98 | 5.26 | 5.72 | 
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.07 | 0.50 | 0.03 | 0.07 | 0.16 | -0.01 | 0.15 | 2.16 | 0.11 | 0.21 | 0.73 | -0.42 | |
| 0.00 | 0.00 | 0.00 | 0.01 | -0.02 | 0.00 | -0.03 | -0.01 | 0.00 | 0.00 | -0.02 | -0.01 | |
| 0.08 | -0.50 | -0.05 | -0.04 | -0.07 | 0.10 | -0.26 | -1.76 | -0.38 | -0.34 | -0.32 | 0.05 | |
| Net Cash Flow | 0.01 | 0.00 | -0.01 | 0.04 | 0.07 | 0.09 | -0.14 | 0.39 | -0.27 | -0.13 | 0.39 | -0.38 | 
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 31.83 | 51.10 | 50.49 | 59.04 | 40.81 | 40.01 | 30.33 | 45.05 | 71.61 | 88.68 | 73.18 | 110.76 | 
| Inventory Days | 4.03 | 3.13 | 2.04 | 8.44 | 13.42 | 16.17 | 34.30 | 26.55 | 45.03 | 36.08 | 32.09 | 16.15 | 
| Days Payable | 572.71 | 458.99 | 519.97 | 525.35 | 641.43 | 542.88 | 575.67 | 455.70 | 502.47 | 481.72 | 58.16 | 119.51 | 
| Cash Conversion Cycle | -536.85 | -404.76 | -467.44 | -457.86 | -587.20 | -486.70 | -511.04 | -384.10 | -385.83 | -356.96 | 47.10 | 7.40 | 
| Working Capital Days | -621.59 | -463.96 | -622.71 | -421.90 | -473.45 | -387.45 | -386.23 | -184.80 | -172.06 | -152.16 | -140.18 | -117.68 | 
| ROCE % | 
Documents
Announcements
- 
        
          Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
          
            9 Oct - Certificate under Reg 74(5) for the quarter ended 30-09-2025
- 
        
          Closure of Trading Window
          
            29 Sep - Trading restriction window from Oct 1, 2025 until 48 hours after unaudited results for quarter/half-year ended Sep 30, 2025.
- 
        
          Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
          
            24 Sep - AGM Sept 23, 2025: consolidated e-voting—five resolutions passed, 385,421 total votes, one dissent.
- 
        
          Shareholder Meeting / Postal Ballot-Outcome of AGM
          
            23 Sep - 108th AGM on Sept 23, 2025; FY2025 financials adopted; Milan Dalal reappointed; Hinal Shah appointed; all ordinary resolutions passed.
- 
        
          Announcement under Regulation 30 (LODR)-Newspaper Publication
          
            1 Sep - Newspaper publication in relation to 108th AGM Notice
Annual reports
- 
    
      Financial Year 2025
      from bse
- 
    
      Financial Year 2024
      from bse
- 
    
      Financial Year 2023
      from bse
- 
    
      Financial Year 2022
      from bse
- 
    
      Financial Year 2021
      from bse
- 
    
      Financial Year 2020
      from bse
- 
    
      Financial Year 2019
      from bse
- 
    
      Financial Year 2018
      from bse
- 
    
      Financial Year 2017
      from bse
- 
    
      Financial Year 2016
      from bse
- 
    
      Financial Year 2015
      from bse
- 
    
      Financial Year 2014
      from bse
- 
    
      Financial Year 2013
      from bse
- 
    
      Financial Year 2012
      from bse
- 
    
      Financial Year 2011
      from bse
Product Profile:[1]
a) Cavisan - Medicated Dental Cream[2]
b) Cavifast - Medicated Dental Cream[3]
c) Cavisan - Gum Astringent[4]
d) Nixoderm[5]